Neurophysiological Effects of Daily Centrum Use on Mood and Well-Being: A Cognalyzer EEG Analysis in Adults Between 40-60

NCT07740135 · tracked via the Priya Life Science Canada tracker

Sponsor

Zentrela Inc

Phase

Observational

Started

2026-07-20

Last updated

2026-09-22

Condition(s) studied

Well-being/Quality of Life

Investigational drug(s) / intervention(s)

Centrum Silver Adult Multivitamin UPC 62107535670 NPN 80141451

Centrum Silver Adult Multivitamin UPC 62107535670 NPN 80141451: Dosage 1 pill per day for 12 weeks

Study summary

The goal of this clinical trial is to learn whether 12 weeks of use of Centrum® Silver Daily Multivitamin can improve mood, and overall well-being in older adults The main questions it aims to answer are:

1. Does daily use of the multivitamin over a 12 week period improve well-being indicators as measured using EEG-based and subjective mood tests?
2. Does perturbation in mood effects due to cognitive load after a battery of cognitive assessments improve after 12 weeks of multivitamin intake.

Eligibility

Sex

ALL

Min age

40 Years

Max age

60 Years

Healthy volunteers

Accepted

Inclusion Criteria: * be between the ages of 40 to 60 * Answered affirmatively that they have consumed, or are interested in consuming the investigational product * Willingness to comply with all study requirements, complete questionnaires, records, and assessments associated with the study and to complete the facility visit * Has given voluntary, written, informed consent to participate in the study Exclusion Criteria: * does not currently consume a multivitamin or dietary supplement that includes more than two micronutrients * Women who are pregnant or breastfeeding * Any objections that preclude the application of the EEG headset * Allergy or sensitivity to any products required for the EEG measurement (e.g. conductive gel) * Subjects with forehead skin/scalp health issues. (eg dermatitis, head lice, etc) * History of a clinically significant adverse event associated with the consumption of a multivitamin product or any of its stated ingredients * History of dementia, schizophrenia or other psychotic disorder, inclusive of alcohol or drug abuse within the last 12 months, interest or participation in drug abuse treatment within the past 60 days, or familial history of psychosis * History of any clinically significant brain injury, based on self-report * The participant is currently experiencing a migraine * Significant cardiovascular event in the past 6 months * Major surgery in the past 3 months * Self-reported HIV-, Hepatitis B- and/or C-positive diagnosis * Impairment from any drug or alcohol during their study visit, as assessed by the Principal Investigator or Sub-Investigator * Individuals who are unable to give informed consent * Any other condition that, in the opinion of the Principal Investigator or Sub-Investigator, may adversely affect the participant's ability to complete the study or its measures, or poses significant risk to the participant.

Primary outcome measure(s)

Change in EEG-Derived Relaxation Level (REL) — Comparison after 12 weeks of product use.
Relaxation Effect Level (REL) is a continuous, algorithmically derived index of relaxation computed from a 2-minute resting EEG segment recorded at 8 scalp electrodes (Fp1, Fp2, T3, T4, P3, P4, O1, O2; Fz ref; 250 Hz, 24 bit). After automated artifact rejection, 200 features are computed across canonical frequency bands, including absolute and relative power spectral density, cross-power spectral density, and connectivity metrics (phase coherence). A support vector machine trained on an independent dataset of EEG labelled with concurrent subjective relaxation ratings uses a fixed feature subset (mRMR/LightGBM selection) to output one score per segment, from -10 (least relaxed) to +10 (most relaxed); higher scores indicate greater relaxation. Model and pipeline were locked prior to enrollment. Each session yields 2 pre-task and 2 post-cognitive-load segments; the reported value is mean post-task REL minus mean pre-task REL within a session, and the two sessions will be compared.
Change in EEG-Derived Mental Confusion Level (COL) — Comparison after 12 weeks of product use.
COL is a continuous, algorithmically derived index of confusion computed from a 2-minute resting EEG segment recorded at 8 scalp electrodes (Fp1, Fp2, T3, T4, P3, P4, O1, O2; Fz ref; 256 Hz). After automated artifact rejection, 200 features are computed across canonical frequency bands, including absolute and relative power spectral density, cross-power spectral density, and connectivity metrics (phase coherence). A support vector machine trained on an independent dataset of EEG labelled with concurrent subjective confusion ratings uses a fixed feature subset (mRMR/LightGBM selection) to output one score per segment, from -10 (least confused) to +10 (most confused); higher scores indicate greater confusion. Model and pipeline were locked prior to enrollment. Each session yields 2 pre-task and 2 post-cognitive-load segments; the reported value is mean post-task COL minus mean pre-task COL within a session, and the two sessions will be compared.

Trial sites (1)

Facility	City	Region	Status
Zentrela Inc Canadian Office	Hamilton	Ontario

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07740135 on ClinicalTrials.gov ↗ ← All trials in Canada